Site Editor
Soo Park, MD
Soo Park, MD
Posted: Monday, June 17, 2024
Neoadjuvant and adjuvant immunotherapy demonstrated comparable results in a health-related quality-of-life analysis for patients with stage III melanoma over a 39-week follow-up. These findings were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting by Alexander M. Menzies, MD, of Melanoma Institute Australia, the University of Sydney, and Royal North Shore and Mater Hospitals, and colleagues (Abstract LBA9584).
The study sought to determine any differences in outcomes between neoadjuvant ipilimumab and plus nivolumab vs adjuvant nivolumab in patients with resectable stage III melanoma. The health-related quality-of-life analysis was based on physical functioning, role functioning, and pain. According to the investigators, there was no significant difference across parameters between the neoadjuvant and adjuvant treatment arms. The current standard of care is adjuvant immunotherapy alone for this patient population.
The study focused on data from the phase III NADINA trial. In total, 261 of 423 randomly assigned patients were evaluated at a 36-week follow-up to assess health-related quality-of-life outcomes.
Disclosure: For disclosures of the study authors, visit coi.asco.org.
JNCCN Spotlights
